Centennial, Colo., (February 19, 2010) – Cochlear, the global leader in implantable hearing solutions, announced today its appointment of Peter Weber, MD, to Chief Medical Officer for Cochlear Americas, effective March 1. In this newly created role, Dr. Weber will be responsible for shaping the strategic direction of medical affairs, health economics and surgical outcomes for the company. In addition, he will work with industry leaders to develop best clinical practices to increase access for millions of patients who could benefit from this life changing technology.
“Dr. Weber brings significant medical experience, industry knowledge and leadership skills to this position based on his past roles as surgeon, clinical investigator and member of several surgical advisory boards including our own,” said Chris Smith, President of Cochlear Americas. “We look forward to his leadership in delivering innovative technology and advancing company-wide initiatives to make implantable hearing technology the standard of care.”
Dr. Weber is board certified in Otolaryngology and Neurotology. He joins Cochlear from the Cleveland Clinic, where he was the Head of the Otology-Neurotology department and Co-Director of the Hearing Implant Program from (7/01) to (present). Prior to joining the Cleveland Clinic, Dr. Weber was Acting Chairman in the Department of Otolaryngology – Head and Neck Surgery at the Medical University of South Carolina. He has served on the Board of Directors of the American Academy of Otolaryngology, is past President of the Board of Governors for Otolaryngology and is an advisor to the AMA/RUC, an expert panel focused on physician work relative value recommendations to CMS. He has published over 100 book chapters and scientific papers and is the Editor-in-Chief of the American Journal of Otolaryngology. Dr. Weber received his BS/MS in engineering from Washington University, St. Louis and medical degree from Albany Medical College. He completed his residency at the University of Pittsburgh Medical Center, his fellowship in Neurotology from University of Iowa and received his MBA from Duke’s Fuqua School of Business
“It is an honor to step into this role and work in tandem with the industry leader and professionals I’ve come to admire and respect over the years,” said Weber. “There is a huge opportunity to make implantable hearing technology available to more patients, and I am committed to make great strides in this area.”
Cochlear is the world leader in implantable hearing solutions. Since launching the first multichannel cochlear implant system more than 25 years ago, Cochlear Limited has brought the miracle of sound to more than 180,000 individuals with hearing loss across the globe. Cochlear Americas markets number one selling products - the Baha® implantable bone-anchored hearing device and Nucleus® cochlear implant technology. For more information about Cochlear Americas’ products, call the Cochlear Hotline at 800/523-5798 (Voice) or visit www.cochlearamericas.com.
Nucleus is a registered trademark, and Cochlear and the elliptical logo are trademarks of Cochlear Limited. Baha is a registered trademark of Cochlear Bone Anchored Solutions AB.